Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1+ Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial

Luu et al., 2024

ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model

Hare et al., 2024

ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model

Hare et al., 2024

ANB032, an Investigational B and T Cell Lymphocyte Attenuator (BTLA) Checkpoint Receptor Agonist, Modulates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology

Muench et al., 2024

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells

Luu et al., 2024

Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2024

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial

Luu et al., 2023

A Phase 2b, Randomized, Double Blind, Placebo Controlled, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Moderate to Severe Atopic Dermatitis

Ehst et al., 2023

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study

Luu et al., 2023

Optimizing PD-1 Agonist Signaling with Membrane-Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2023

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Demonstrated Modulation of Peripheral T Cell Activity and Reduction of Circulating PD-1 high Expressing CD4 and CD8 T Cells in a Phase 1 Healthy Volunteer Clinical Trial

Dahl et al., 2022

A Phase 2b, Randomized, Double Blind, Placebo Controlled, Multicenter, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

Silverberg et al., 2023

Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune Diseases

Hare et al., 2023

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibited T Cell Proliferation, Reduced Inflammatory Cytokines, and Down Modulated BTLA Expression on Circulating T and B Cells in Phase 1, Progresses Into a Phase 2 Study in Atopic Dermatitis

Luu et al., 2023